Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of N-acetylprocainamide

  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Since N-acetylprocainamide was identified in the urine of patients receiving procainamide, this compound has been studied both as a metabolite of procainamide and as a separate antiarrhythmic agent. N-acetylprocainamide absorption following oral administration is more than 80% complete. 59 to 89% of N-acetylprocainamide is excreted unchanged in the urine in subjects with normal renal function. Deacetylation of N-acetylprocainamide to procainamide is a minor route of N-acetylprocainamide elimination.

The half-life of N-acetylprocainamide in patients with normal renal function has been reported to vary between 4.3 and 15.1 hours. Total body clearance (mean ± SD) of N-acetylprocainamide in patients with normal renal function has been reported to range from 2.08 ± 0.36ml/min/kg to 3.28 ± 0.52ml/min/kg. There is a linear relationship between N-acetylprocainamide clearance and creatinine clearance. The half-life of N-acetylprocainamide in functionally anephric patients may be as long as 42 hours: however, it can be effectively cleared from plasma by haemodialysis. N-acetylprocainamide is 10% protein-bound. There is an age-related decline in N-acetylprocainamide clearance, mostly due to the decrease in creatinine clearance that occurs with ageing. In the neonate, the half-life of N-acetylprocainamide is prolonged. Several therapeutic trials carried out to assess the effectiveness of N-acetylprocainamide in suppressing chronic ventricular premature beats have now been reported. If there is a therapeutic response to N-acetylprocainamide it will probably occur at a plasma concentration between 15 and 25μg/ml. A high degree of overlap has been reported between the concentration range associated with arrhythmic suppression and the range of concentrations where intolerable side effects begin to occur. No severe cardiac toxicity has been reported with oral therapy despite plasma concentrations as high as 40μg/ml. However, hypotension has been reported in association with a rapid intravenous bolus of N-acetylprocainamide. A maximum intravenous infusion rate of 50mg/min has been recommended.

N-acetylprocainamide in patients receiving procainamide: however, N-acetylprocainamide concentrations remain below the therapeutic range in patients with normal renal function. In patients with renal failure receiving procainamide, N-acetylprocainamide concentrations rise dramatically.

The dose of N-acetylprocainamide must be adjusted in patients with renal insufficiency, and it should be used more cautiously in the very old and very young. N-acetylprocainamide plasma concentration monitoring would be valuable clinically in patients with renal insufficiency receiving either N-acetylprocainamide or procainamide, and in the very young and the aged.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Atkinson, A.J. Jr; Krumlovsky, F.A.; Huang, C.M. and del Greco, F.: Hemodialysis for severe procainamide toxicity: Clinical and pharmacokinetic observalions. Clinical Pharmacology and Therapeutics 20: 585–592 (1976).

    PubMed  Google Scholar 

  • Atkinson, A.J. Jr; Lee, W.; Quinn, M.L.; Kushner, W.; Nevin, M.J. and Strong, J.M.: Dose-ranging trial of n-acetylprocainamide in patients with premature ventricular contractions. Clinical Pharmacology and Therapeutics 21: 578–587 (1977).

    Google Scholar 

  • Bagwell, E.E.; Drayer, D.E.; Reidenberg, M.M. and Pruett, J.K.: Effects of the n-acetyl metabolite of procainamide on transmembrane action potentials of canine His Purkinje cells. Clinical Research 22: 676A (1974).

    Google Scholar 

  • Bagwell, E.E.; Walle, T.; Drayer, D.E.; Reidenberg, M.M. and Pruett, J.K.: Correlation of the electrophysiological and antiarrhythmic properties of the n-acetyl metabolite of procainamide with plasma and tissue drug concentrations in the dog. Journal of Pharmacology and Experimental Therapeutics 197: 38 (1976).

    PubMed  CAS  Google Scholar 

  • Carr, K., Woosley, R.L. and Oates, F.A.: Simultaneous quantification of procainamide and n-acetylprocainamide with high pressure liquid chromatography. Journal of Chromatography 129: 365–368 (1976).

    Google Scholar 

  • Drayer, D.E.; Lowenthal, D.T.; Woosley, R.L.; Nies, A.S.; Schwartz, A. and Reidenberg, M.M.: Cumulation of n-acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function. Clinical Pharmacology and Therapeutics 22: 63–69 (1977).

    PubMed  CAS  Google Scholar 

  • Dreyfuss, J.: Ross, J.J. Jr and Schreiber, E.C.: Absorption, excretion and biotransformation of procainamide-C14 in the dog and Rhesus monkey. Arzeinittel-Forschung 7: 948–951 (1971).

    Google Scholar 

  • Dreyfuss, J.: Bigger, J.T. Jr; Cohen, A.I. and Schreiber, E.C.: Metabolism of procainamide in Rhesus monkey and man. Clinical Pharmacology and Therapeutics 13: 366–371 (1972).

    PubMed  CAS  Google Scholar 

  • Dutcher, J.S.; Strong, J.M.; Lucas, S.V.; Lee, W. and Atkinson, A.J. Jr: Procainamide and n-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology. Clinical Pharmacology and Therapeutics 22: 447–457 (1977).

    PubMed  CAS  Google Scholar 

  • Elson, J.; Strong, J.M.; Lee, W. and Atkinson, A.J., Jr: Antiarrhythmic potency of n-acetylprocainamide. Clinical Pharmacology and Therapeutics 17: 134–140 (1975).

    PubMed  CAS  Google Scholar 

  • Evans, D.A.P.: Genetic variations in acetylation of isoniazid and other drugs. Annals of the New York Academy of Sciences 151: 723–733 (1968).

    PubMed  CAS  Google Scholar 

  • Evans, D.A.P. and White, T.A.: Human acetylation polymorphism. Journal of Laboratory and Clinical Medicine 63: 394–403 (1964).

    PubMed  CAS  Google Scholar 

  • Evans, D.A.P.; Manley, K.A. and McKusick, U.A.: Genetic control of isoniazid metabolism in man. British Medical Journal 2: 485–491 (1960).

    Article  PubMed  CAS  Google Scholar 

  • Galeazzi, R.L.; Sheiner, L.B.; Lockwood, T. and Benet, L.Z.: The renal elimination of procainamide. Clinical Pharmacology and Therapeutics 19: 55–62 (1976).

    PubMed  CAS  Google Scholar 

  • Galeazzi, R.L; Omar-Amberg, C. and Karlaganis, G.: N-acetylprocainamide kinetics in the elderly. Clinical Pharmacology and Therapeutics 29: 440–446 (1981).

    Article  PubMed  CAS  Google Scholar 

  • Gibson, T.P.; Matusik, E.J. and Briggs, W.A.: N-acetylprocainamide levels in patients with end-stage renal failure. Clinical Pharmacology and Therapeutics 19: 206–212 (1975).

    Google Scholar 

  • Gibson, T.P.; Atkinson, A.J., Jr; Matusik, E.; Nelson, L.D. and Briggs, W.A.: Kinetics of procainamide and n-acetylprocainamide in renal failure. Kidney International 12: 422–429 (1977a).

    Article  PubMed  CAS  Google Scholar 

  • Gibson. T.P.; Matusik, E.J.; Nelson, L.D. and Briggs, W.A.: Artificial kidneys and clearance calculations. Clinical Pharmacology and Therapeutics 20: 720–726 (1977b).

    Google Scholar 

  • Graffner, C.: Elimination rate of n-acetylprocainamide after a single intravenous dose of procainamide hydrochloride in man. Journal of Pharmacokinetics and Biopharmaceutics 3: 69–76 (1975).

    PubMed  CAS  Google Scholar 

  • Jaillon, P. and Winkle, R.A.: Electrophysiologic comparative study of procainamide and n-acetylprocainamide in anesthetized dogs: Concentration-response relationships. Circulation 60: 1385–1394 (1975).

    Article  Google Scholar 

  • Jaillon, P.; Rubenson, D.; Peters, F.; Mason, J.W. and Winkle, R.A.: Electrophysiologic effects of N-acetylprocainamide in human beings. American Journal of Cardiology 47: 1134–1140 (1981).

    Article  PubMed  CAS  Google Scholar 

  • Karlsson, E.; Molin, L; Norlander, B. and Sjoqvist, F.: Acetylation of procaineamide in man studied with a new gas Chromatographic method. British Journal of Clinical Pharmacology 1: 467–475 (1974).

    Article  PubMed  CAS  Google Scholar 

  • Kates, R.E.; Jaillon, P.; Rubenson, D.S. and Winkle, R.A.: Intravenous n-acetylprocainamide disposition kinetics in coronary artery disease. Clinical Pharmacology and Therapeutics 28: 52–57 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Kluger, J.; Drayer, D.; Reidenberg, M.; Ellis. G.; Lloyd, V.; Tybert, T. and Hayes, J.: The clinical pharmacology and antiarrhythmic efficacy of acetylprocainamide in patients with arrhythmias. American Journal of Cardiology 45: 1250–1257 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Lee, W.; Strong, J.M.; Kehve, R.F.; Dutcher, J.S. and Atkinson, A.J., Jr: Antiarrhythmic efficacy of n-acetylprocainamide in patients with premature ventricular contractions. Clinical Pharmacology and Therapeutics 19: 508–514 (1976).

    PubMed  CAS  Google Scholar 

  • Lertora, J.J.L.; Atkinson, A.J.; Kushner, W.; Nevin, M.J.; Lee, W.; Jones, C. and Schmid, F.R.: Long-term antiarrhythmic therapy with n-acetylprocainamide. Clinical Pharmacology and Therapeutics 25: 273–282 (1979).

    PubMed  CAS  Google Scholar 

  • Lima, J.J. and Jusko, W.J.: Determination of procainamide acetylator status. Clinical Pharmacology and Therapeutics 23: 25–29 (1978).

    PubMed  CAS  Google Scholar 

  • Lima, J.J.; Kuritzky, P.M.; Schentag, J.J. and Jusko, W.J.: Fetal uptake and neonatal disposition of procainamide and its acetylated metabolite. A case report. Pediatrics 61: 491–493 (1978).

    PubMed  CAS  Google Scholar 

  • Lima, J.J.; Conti, D.R.; Goldfarb, A.L.; Tilstone, W.J.; Golden, L.H. and Jusko. W.J.: Clinical pharmacology of procainamide infusions in relation to acetylator phenotype. Journal of Pharmacokinetics and Biopharmaceutics 7: 69–85 (1979).

    PubMed  CAS  Google Scholar 

  • Mark, L.C.; Kayden, H.J.; Steele, J.M.; Cooper, J.R.; Berlin, I.; Rovenstine, E.A. and Brodie, B.B.: The phsyiological disposition and cardiac effects of procainamide. Journal of Pharmacology 102: 5 (1951).

    CAS  Google Scholar 

  • Minchen, R.F.. Zlett, K.F. and Paterson, J.W.: Antiarrhythmic potency of procainamide and n-acetylprocainamide in rabbits. European Journal of Pharmacology 47: 51–56 (1978).

    Article  Google Scholar 

  • Pearson, J.F.: Maternal and fetal acid-base balance; in Beard and Nathanrelsz (Eds) Fetal Physiology and Medicine: The Basis of Perinatology, pp.492–509 (W.B. Saunders, New York 1976).

    Google Scholar 

  • Reidenberg, M.M.; Drayer, D.E.; Levy, M. and Warner, H.: Polymorphic acetylation of procainamide in man. Clinical Pharmacology and Therapeutics 17: 722–730 (1975).

    PubMed  CAS  Google Scholar 

  • Reidenberg, M.M.; Camacho, M.; Kluger, J. and Drayer, D.E.: Ageing and renal clearance of procainamide and acetylprocainamide. Clinical Pharmacology and Therapeutics 28: 732–735 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Roden, D.M.; Reele. S.B.; Higgins, S.B.; Wilkinson, G.R.; Smith, R.F.; Oates, J.A. and Woosley, R.L.: Antiarrhythmic efficacy, pharmacokinetics and safety of n-acetylprocainamide in human subjects: Comparison with procainamide. American Journal of Cardiology 46: 463–468 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Ruo, T.I.; Thenot, J.P.; Stec, O.P. and Atkinson, A.J. Jr: Plasma concentrations of desethyl n-acetylprocainamide in patients treated with procainamide and n-acetylprocainamide. Therapeutic Drug Monitoring. In press (1982).

  • Shukur, L.R.; Powers. J.L.; Marques, R.A.; Winter, M.E. and Sadee, W.: Measurement of procainamide and n-acetylprocainamide in serum by high-pressure liquid chromatography. Clinical Chemistry 23: 636–638 (1977).

    PubMed  CAS  Google Scholar 

  • Simons, K.J. and Levy, R.H.: GLC determination of procainamide in biological fluids. Journal of Pharmaceutical Sciences 64: 1967–1970 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Sonnlag, C. and Karlsson, E.: Comparative antiarrhythmic efficacy of intravenous n-acetylprocainamide and procainamide. European Journal of Clinical Pharmacology 15: 311–317 (1979).

    Article  Google Scholar 

  • Stec, G.P.; Atkinson, A.J.; Nevin, M.J.; Thenot, J.P.; Ruo, T.I.; Gibson, T.P.: Ivanovitch, P. and del Greco, F.: N-acetylprocainamide pharmacokinetics in functionally anephric patients before and after pertubation by hemodialysis. Clinical Pharmacology and Therapeutics 26: 618–628 (1979).

    PubMed  CAS  Google Scholar 

  • Stec, G.P.; Ruo, T.I.; Thenot, J.P.; Atkinson. A.J. Jr; Morita, Y. and Lertora, J.J.L.: Kinetics of n-acetylprocainamide deacetyiation. Clinical Pharmacology and Therapeutics 28: 659–666 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Strong, J.M.; Dutcher, J.S.; Lee, W. and Atkinson, A.J.: Pharmacokinetics in man of the n-acetylated metabolite of procainamide. Journal of Pharmacokinetics and Biopharmaceutics 3: 223–235 (1975a).

    PubMed  CAS  Google Scholar 

  • Strong, J.M.; Dutcher, J.S.; Lee, W. and Atkinson, A.J.: Absolute bioavailability in man of n-acetylprocainamide determined by a novel stable isotope method. Clinical Pharmacology and Therapeutics 18: 613–622 (1975b).

    PubMed  CAS  Google Scholar 

  • Weddle, O.H. and Mason, W.D.: Rapid determination of procainamide and its n-acetyl derivative in human plasma by high pressure liquid chromatography. Journal of Pharmaceutical Sciences 66: 874–875 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Wesley-Hadzija, B. and Mattocks, A.M.: Quantitative thin-layer Chromatographic method for the determination of procainamide and its major metabolite in plasma. Journal of Chromatography 143: 307–313 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Wierzchowiecki, M.; Michalowski, D.; Lowicki, Z.; Ocholny, A.; Grzeskowiak, A. and Tomaszkiewicz, T.: Pharmacokinetic studies of procainamide (PA) and n-acetylprocainamide (NAPA) in healthy subjects. International Journal of Clinical Pharmacology, Therapy and Toxicology 18: 272–276 (1980).

    CAS  Google Scholar 

  • Winkle, R.A.; Jaillon, P.; Kates, R.E. and Peters, F.: Clinical pharmacology and antiarrhythmic efficacy of n-acetylprocainamide. American Journal of Cardiology 47: 123–130 (1981).

    Article  PubMed  CAS  Google Scholar 

  • Wyman, M.G.; Goldreyer, B.N.; Cannom, D.S.; Ludden, T.M. and Lalka, D.: Factors influencing procainamide total body clearance in the immediate postmyocardial infarction period. Journal of Clinical Pharmacology 21: 20–25 (1981).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology Division, Stanford University Medical Center, Stanford, California, 94305, USA

    Stuart J. Connolly &  Robert E. Kates (Assistant Professor of Medicine)

Authors
  1. Stuart J. Connolly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert E. Kates
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Connolly, S.J., Kates, R.E. Clinical Pharmacokinetics of N-acetylprocainamide. Clin Pharmacokinet 7, 206–220 (1982). https://doi.org/10.2165/00003088-198207030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-198207030-00002

Keywords

Search

Navigation